ClinicalTrials.gg
CompletedNCT00191165Updated Jun 10, 2009Results posted

Efficacy and Safety of a High Dosage Compared to the Label Dosage of Somatropin in Early Pubertal Stage Children With Growth Hormone Deficiency

A Phase 3 interventional study of Somatropin and Somatropin in Growth Hormone Deficiency, sponsored by Eli Lilly and Company. Completed at 10 sites in Italy. Open to participants aged Up to 14 Years. Per ClinicalTrials.gov, last updated 2009-06-10.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
27
Allocation
Randomized
Ages
Up to 14 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 60 studies testing Human Growth Hormone in Dwarfism, Pituitary — 3 open to participants now, 3 under way, 2 of them phase 3. Human Growth Hormone · Dwarfism, Pituitary.

Enrollment
42nd of 60
27 · median 66
Started
2004
with 4 others
Phase 3
23 of 60
2 open now
Registered
9th of 60
by date
Lead sponsor
3 of 60
Eli Lilly and Company

Among the 60 studies testing Human Growth Hormone in Dwarfism, Pituitary, this one is the 42nd largest by enrollment, is one of 5 that started in 2004, is one of 23 in phase 3, and was the 9th registered.

Dwarfism, Pituitary

252 studies on the registry are indexed under Dwarfism, Pituitary; 30 are open to participants now.

Browse Dwarfism, Pituitary studies →

Open to participants now

3 of the 60 studies testing Human Growth Hormone in Dwarfism, Pituitary are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About Human Growth Hormone

Human Growth Hormone: first FDA approval 1986 (HUMATROPE), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 20 Dwarfism, Pituitary studies recruiting now, 5 (25%) set no upper age limit and 12 (60%) stop at 75 or younger; 11 take children under 18; 4 take healthy volunteers.

This study: Up to 14 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies testing Human Growth Hormone in Dwarfism, Pituitary, or all of them as a file.
02

Study summary

Multi-center, randomized, controlled, open-label, phase III study comparing the effects of two different dosages of somatropin treatment (in-label or doubled) after 12 and 24 months of treatment, on height velocity in early pubertal children with growth hormone deficiency (GHD). The study will be conducted in Italy. Approximately 26 subjects will participate in this study, distributed as 13 in the in-label dosage group (group A) and 13 in the doubled dosage group (group B).

03

Conditions studied

  • Growth Hormone Deficiency

Browse trials for

04

Who can participate

Ages eligible
Up to 14 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Height velocity (cm/y) less than 25th percentile at the time of diagnosis.
  • diagnosis of GHD
  • Replacement therapy at label dosage (from 0.025 to 0.035 mg/kg/day) must be started at least 1 year before the enrolment in this study, but at most 3 years before enrolment
  • Bone age less than 12 years for girls and less than 14 years for boys. This assessment should be made by the central reader of bone ages, based on the x-ray taken at Visit 0.
  • obtained from either both of the subject's parents or legal representative.

Exclusion criteria

Exclusion Criteria:

  • Pubertal clinical stage less than 2 and greater than 3 according to Tanner score (for male subjects a volume of testicle greater than 15 mL).
  • Any evidence of active . In case of previous surgical removal of both diencephalic and hypophysial masses, an MRI, performed within six months before enrollment into the study, must exclude the growth of residual tumoral tissue.
  • Any known chronic disease such as diabetes mellitus, hepatic disease (defined by elevated liver enzymes 3-fold the ranges), renal disease with creatinine levels greater than 130 micromol/L, or congestive heart failure.
  • therapy in supra physiological doses (inhaled corticoids will be accepted if below 3 puffs/day, for no more than 10 days consecutively).
  • Current or previous therapy with any therapy that may directly influence growth, including growth hormone releasing hormone, estrogens and anabolic steroids.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    1

    Doubled dosage

    Drug: Somatropin

  • Active comparator
    2

    In-label dosage

    Drug: Somatropin

Interventions

06

What researchers measure

Primary outcomes

  1. Height Velocity Standard Deviation Score (SDS) at 12-Month Endpoint

    Height velocity (difference between 2 height measurements, divided by years elapsed between measurements) SDS was derived by subtracting age and gender-matched population mean height velocity from patient's height velocity (based on measurements 12 months apart) then dividing this value by age and gender-matched population height velocity SD.

    Time frame: 12-Months

Secondary outcomes

  1. Change From Baseline to 12-Month and 24-Month Endpoints in Height Standard Deviation Score (SDS)

    This was derived by subtracting the age-and-gender-matched population 50th percentile height from the patient's height and then dividing this value by the age-and-gender-matched population height SD.

    Time frame: Baseline, 12-Months, 24-Months

  2. Height Velocity Standard Deviation Score (SDS) at 24 Month Endpoint

    Height velocity (difference between 2 height measurements, divided by years elapsed between measurements) SDS was derived by subtracting age and gender-matched population mean height velocity from patient's height velocity (based on measurements 12 months apart) then dividing this value by age and gender-matched population height velocity SD.

    Time frame: 24 Months

07

Results

Posted Jun 8, 2009

Participant flow

Participant flow — Overall Study
MilestoneHigh Dose SomatropinLabel Dose Somatropin
Started1413
Completed1211
Not completed22
Withdrew: Adverse event20
Withdrew: Protocol violation01
Withdrew: Participant moved away01

Outcome measures

PrimaryHeight Velocity Standard Deviation Score (SDS) at 12-Month Endpoint

Height velocity (difference between 2 height measurements, divided by years elapsed between measurements) SDS was derived by subtracting age and gender-matched population mean height velocity from patient's height velocity (based on measurements 12 months apart) then dividing this value by age and gender-matched population height velocity SD.

Time frame:
12-Months
Reported as:
Mean · standard deviation score
Height Velocity Standard Deviation Score (SDS) at 12-Month Endpoint
standard deviation scoreHigh Dose SomatropinLabel Dose Somatropin
Height Velocity Standard Deviation Score (SDS) at 12-Month Endpoint1.83 ± 0.911.38 ± 1.41
Statistical analysis
  • High Dose Somatropin vs Label Dose Somatropin · ANOVA · p = 0.340 · Mean difference (net): 0.45 · 95% CI -0.50 to 1.40Mean Difference = High Dose - Label Dose
SecondaryChange From Baseline to 12-Month and 24-Month Endpoints in Height Standard Deviation Score (SDS)

This was derived by subtracting the age-and-gender-matched population 50th percentile height from the patient's height and then dividing this value by the age-and-gender-matched population height SD.

Time frame:
Baseline, 12-Months, 24-Months
Reported as:
Least squares mean · standard deviation score
Change From Baseline to 12-Month and 24-Month Endpoints in Height Standard Deviation Score (SDS)
standard deviation scoreHigh Dose SomatropinLabel Dose Somatropin
12-Month Height SDS Change (N=14, N=12)0.49 ± 0.120.34 ± 0.13
24-Month Height SDS Change (N=13, N=11)0.88 ± 0.170.40 ± 0.18
Statistical analysis
  • High Dose Somatropin vs Label Dose Somatropin · ANOVA · p = 0.388 (P-value for 12-Month Height SDS Change) · Mean difference (net): 0.16 · 95% CI -0.21 to 0.53Mean Difference = High Dose - Label Dose
  • High Dose Somatropin vs Label Dose Somatropin · ANOVA · p = 0.061 (P-value for 24-Month Height SDS Change) · Mean difference (net): 0.49 · 95% CI -0.02 to 0.99Mean Difference = High Dose - Label Dose
SecondaryHeight Velocity Standard Deviation Score (SDS) at 24 Month Endpoint

Height velocity (difference between 2 height measurements, divided by years elapsed between measurements) SDS was derived by subtracting age and gender-matched population mean height velocity from patient's height velocity (based on measurements 12 months apart) then dividing this value by age and gender-matched population height velocity SD.

Time frame:
24 Months
Reported as:
Mean · standard deviation score
Height Velocity Standard Deviation Score (SDS) at 24 Month Endpoint
standard deviation scoreHigh Dose SomatropinLabel Dose Somatropin
Height Velocity Standard Deviation Score (SDS) at 24 Month Endpoint2.58 ± 1.861.45 ± 1.06
Statistical analysis
  • High Dose Somatropin vs Label Dose Somatropin · ANOVA · p = 0.088 · Mean difference (net): 1.13 · 95% CI -0.18 to 2.44Mean Difference = High Dose - Label Dose

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
High Dose Somatropin———
Label Dose Somatropin———
Most frequent serious events
Most frequent serious events
EventHigh Dose SomatropinLabel Dose Somatropin
Vertebral injuryInjury, poisoning and procedural complications1/140/13
Most frequent other events
Showing 10 of 26
Most frequent other events
EventHigh Dose SomatropinLabel Dose Somatropin
HeadacheNervous system disorders3/140/13
GynaecomastiaReproductive system and breast disorders3/141/13
PyrexiaGeneral disorders2/142/13
InfluenzaInfections and infestations2/140/13
Insulin resistanceMetabolism and nutrition disorders2/140/13
ScoliosisMusculoskeletal and connective tissue disorders2/140/13
Melanocytic naevusNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/141/13
RetinoschisisEye disorders0/141/13
Genital infectionInfections and infestations0/141/13
PharyngitisInfections and infestations1/141/13

Baseline characteristics

Age Continuous
Age Continuous(years)High Dose SomatropinLabel Dose SomatropinTotal
Mean13.5 ± 1.213.0 ± 1.513.3 ± 1.3
Sex: Female, Male
Sex: Female, Male(Participants)High Dose SomatropinLabel Dose SomatropinTotal
Female134.0
Male131023.0
Region of Enrollment
Region of Enrollment(participants)High Dose SomatropinLabel Dose SomatropinTotal
Italy141327.0
Race/Ethnicity
Race/Ethnicity(participants)High Dose SomatropinLabel Dose SomatropinTotal
Caucasian141226.0
Other011.0
Baseline Predicted Height
Baseline Predicted Height(centimeters)High Dose SomatropinLabel Dose SomatropinTotal
Mean168 ± 6.8169 ± 10.7168 ± 8.7
Baseline Predicted Height Standard Deviation Score (SDS)
Baseline Predicted Height Standard Deviation Score (SDS)(standard deviation score)High Dose SomatropinLabel Dose SomatropinTotal
Mean-0.9 ± 0.8-0.5 ± 1.0-0.7 ± 0.9
Body Mass Index
Body Mass Index(kilograms per square meter (kg/m2))High Dose SomatropinLabel Dose SomatropinTotal
Mean18.9 ± 3.219.4 ± 3.719.2 ± 3.4
Bone Age
Bone Age(years)High Dose SomatropinLabel Dose SomatropinTotal
Mean12.4 ± 0.712.1 ± 1.012.2 ± 0.8

4 further baseline measures are reported on the registry.

08

Study locations

10 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Bari, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Bologna, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Catania, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Milano, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Novara, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Parma, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Pavia, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Pisa, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Torino, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Verona, Italy
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2004, a primary completion of Apr 2008 and a completion of Apr 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2009, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2005
First posted
Sep 19, 2005
Start
Mar 2004
Primary completionActual
Apr 2008
CompletionActual
Apr 2008
Results first posted
Jun 8, 2009
Last update
Jun 10, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 10, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00191165
First posted
Sep 19, 2005
Start date
Mar 2004
Primary completion
Apr 2008
Completion
Apr 2008
Results posted
Jun 8, 2009
Last update
Jun 10, 2009

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study chair · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human Growth Hormone

Start the discussion